Adicet Bio ACET shares are trading higher on Wednesday after the company announced it will not be proceeding with its previously announced public offering of common stock.
Adicet Bio is a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. The company is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients.
Adicet Bio shares were trading up 35% at $13.76 at the time of publication. The stock has a 52-week high of $69.16 and a 52-week low of $6.02.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
